Background:

MEGF9 [multiple EGF (epidermal growth factor)-like-domains 9], a novel transmembrane protein with multiple EGF-like repeats, is predominantly expressed in the developing and adult CNS (central nervous system) and PNS (peripheral nervous system). The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins. Following one single pass transmembrane domain, a highly conserved short intracellular domain with potential phosphorylation sites is present. The protein was recombinantly expressed and characterized as a tissue component. MEGF9 represents a novel putative receptor, expressed in neuronal and non-neuronal tissues, that is regulated during development and could function as a guidance or signalling molecule.

Applications:

WB

Name of antibody:

MEGF9

Immunogen:

Synthesized peptide derived from internal of human MEGF9.

Full name:

multiple EGF-like-domains 9

Synonyms:

EGFL5

SwissProt:

Q9H1U4

WB Predicted band size:

63 kDa

WB Positive control:

COLO cells lysate

WB Recommended dilution:

500-3000